Top Type 1 Diabetes Advances of Fiscal Year 2023
Breakthrough T1D highlights the top type 1 diabetes advances we've seen during fiscal year 2023, including cures and life-improving therapies.
Breakthrough T1D & NIH Workshop at the Intersection of Immunology and Bioengineering
Breakthrough T1D and NIH bring together top scientists and engineers to strategize on how to allow implanted beta cells to…
Teplizumab (the Therapy that Delays T1D By Nearly 3 Years) Isn’t Approved…Yet
The FDA issued a letter to Provention Bio for the use of teplizumab to delay T1D in at-risk individuals, meaning…
FDA Advisory Committee Recommends that Teplizumab Receives Approval
An FDA Advisory Committee weighed the evidence, and the results were positive: They recommended that the FDA approve teplizumab for…
Investigations by Leading Immune-Mediated Disease Research Organizations
Breakthrough T1D has partnered with the Lupus Research Alliance and the National Multiple Sclerosis Society to advance the understanding of…
Can a Psoriasis Drug Halt or Reverse Type 1 Diabetes?
Type 1 diabetes is one of the only major autoimmune diseases that doesn't have a disease-modifying therapy. A Breakthrough T1D clinical…
It’s Official: Teplizumab is Under Review by the FDA
The FDA regulatory review is now under way for teplizumab, to prevent or delay T1D in at-risk individuals. The target…
Discovery to Translation: Clinical Trial of a JAK Inhibitor in T1D
A Breakthrough T1D-funded clinical trial will test if a JAK inhibitor will preserve beta cell function in children and young…
What If You Could Halt Immune Cell Memory?
JDRF-funded researchers have discovered a protein on immune cells that, when it is disabled, could halt immune cell memory.
The Power of the Patient Voice: Breakthrough T1D Video
In the words of Colin Dayan, M.D., Ph.D., professor of clinical diabetes and metabolism at Cardiff University: “Type 1 diabetes…
